Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
The discontinuation of the Phase 3 study for Trodelvy and KEYTRUDA in NSCLC is a significant setback for both Merck and Gilead, impacting their competitive positioning in the oncology market. This event necessitates a reevaluation of their strategies and potential partnerships in this therapeutic area.
Phase III
non-small cell lung cancer
Status
Positive
Sponsor
Merck
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The discontinuation of the Phase 3 study for Trodelvy and KEYTRUDA in NSCLC is a significant setback for both Merck and Gilead, impacting their competitive positioning in the oncology market. This event necessitates a reevaluation of their strategies and potential partnerships in this therapeutic area.
Why it matters
The discontinuation of the Phase 3 study for Trodelvy and KEYTRUDA in NSCLC is a significant setback for both Merck and Gilead, impacting their competitive positioning in the oncology market. This event necessitates a reevaluation of their strategies and potential partnerships in this therapeutic area.
What changed
Trial Update
Analysis
The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.
The discontinuation of the Phase 3 study for Trodelvy and KEYTRUDA in NSCLC is a significant setback for both Merck and Gilead, impacting their competitive positioning in the oncology market. This event necessitates a reevaluation of their strategies and potential partnerships in this therapeutic area.
Monitor for further data releases from the study and any strategic shifts from Merck or Gilead regarding their NSCLC portfolios.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.